Clinical Study of the Medeon Biodesign XPro™

Inclusion Criteria: * Patient is \> 18 years old * Patient is scheduled for percutaneous BAV, TAVR/TAVI, EVAR, or TEVAR involving access through the femoral artery using an 8-18 Fr introducer sheath * Patient is able to undergo emergent vascular surgery if a complication related to the vascular closure necessitates such surgery * Patient, or authorized representative, signs a written Informed Consent form to participate in the study, prior to any study mandated procedures * Patient is willing and able to complete follow-up Exclusion Criteria: * Prior intra-aortic balloon pump at access site * Patients with severe claudication, iliac or femoral artery diameter stenosis greater than 50% * Common femoral artery lumen diameter is \< 6 mm * Prior target artery closure with any closure device \< 90 days, or closure with manual compression ≤ 30 days prior to index procedure * Prior vascular surgery, vascular graft, or stent in region of access site * Patients receiving glycoprotein IIb/IIIa inhibitors before, during, or after the catheterization procedure * Patients with significant anemia ((Hgb \< 10 g/dL, Hct \< 30%) * Patient with known bleeding disorder including thrombocytopenia (platelet count \< 100,000), thrombasthenia, hemophilia or Von Willebrand's disease * Patients with renal insufficiency (serum creatinine level \> 221µmol/L) or renal transplant * Known allergy to contrast reagent * Inability to tolerate aspirin and/or other anticoagulation treatment * Planned anticoagulation therapy post-procedure such that ACT is expected to be elevated above 350 seconds for more than 24 hours after the procedure * Connective tissue disease (e.g., Marfan's Syndrome) * Thrombolytics (e.g. t-PA, streptokinase, urokinase), Angiomax (bivalirudin) or other thrombin-specific anticoagulants ≤ 24 hours prior to the procedure * Recent (within 8 weeks) cerebrovascular accident or Q-wave myocardial infarction * Patients who are morbidly obese BMI \> 40 kg/m2 * Planned major intervention or surgery within 30 days following the interventional procedure * Patients who are unable to ambulate at baseline * Currently participating in a clinical study of an investigational device or drug that has not completed study endpoint * Known allergy to any device component * Patient is known or suspected to be pregnant or lactating * Life expectancy \< 1 year as judged by the investigator * Patient has other medical, social or psychological problem that in the opinion of the investigator precludes them from participating Intra-Procedure * Access site above the most inferior border of the inferior epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks * Access site in the profunda femoris or superficial femoral arteries, or the bifurcation of these vessels * Ipsilateral femoral venous sheath during the catheterization procedure * Common femoral artery calcium, which is fluoroscopically visible * Patients where there is difficulty inserting the introducer sheath or greater than 2 ipsilateral arterial punctures at the start of the catheterization procedure * Difficulty in obtaining vascular access resulting in multiple arterial punctures and/or posterior arterial puncture * Evidence of a pre-existing hematoma, arteriovenous fistula, or pseudoaneurysm at the access site * Patients with intra-procedural bleeding around access site * Evidence of active systemic or local groin infection * Patients receiving glycoprotein IIb/IIIa inhibitors during, or after the catheterization procedure